From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

DoD Awards 42M Contract for Japanese Encephalitis Vaccine

by Global Biodefense Staff
March 16, 2016
Japanese Encephalitis Vaccine

The U.S. Department of Defense has recently awarded a notable contract for medical countermeasures for military and contractor personnel and their family members.

Intercell USA Inc. of Gaithersburg, Maryland, a subsidiary of Valneva SE, has been awarded a maximum $32,488,750 firm-fixed-price, indefinite-quantity contract for a supply of the Japanese encephalitis vaccine.

Under the terms of the agreement, Valneva will supply IXIARO, the only Japanese encephalitis vaccine approved in the U.S., to the Defense Logistics Agency (DLA), Supply Center of the US Department of Defense. First deliveries are expected to commence in the coming weeks.

This is a one-year base contract with a one-year option period, worth up to a total of $42 million.

“With a mortality rate that can reach 30% and neurological sequelae for half of the survivors, Japanese  encephalitis is a clear danger to the thousands of military personnel – and their families – that are stationed in areas where the disease is endemic,” commented Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva. “We feel honored that the US Department of Defence continues to acknowledge our vaccine as the best protection against the disease”.

Japanese encephalitis is a very serious and growing public health threat in Asia. The US Department of Defense has been using IXIARO to protect the near 360,000 U.S. military and civilian personnel, and their families, working and living in endemic countries since 2010.

From Our Partners
Tags: Awards

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
Biosecurity

Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies

June 14, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC